ClinicalTrials.Veeva

Menu
A

Advanced ENT and Allergy | Breckenridge

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

OTO-313
Dupilumab
OTO-413
AD109
Omalizumab
Aroxybutynin
Fluticasone Propionate
Verekitug
GB001
Mometasone furoate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 26 total trials

A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)

Post-market study to continue to evaluate the effectiveness of the RhinAer ARC Stylus for chronic rhinitis.

Active, not recruiting
Chronic Rhinitis
Device: RhinAer ARC Stylus

The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in...

Enrolling
Chronic Rhinosinusitis with Nasal Polyps
Drug: Placebo
Drug: Verekitug (UPB-101)
Locations recently updated

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

Primary Objective:* To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinu...

Active, not recruiting
Allergic Fungal Rhinosinusitis
Drug: Dupilumab SAR231893
Drug: Placebo

Primary Objective-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smellSecondary Objec...

Active, not recruiting
Asthma
Chronic Rhinosinusitis With Nasal Polyps
Drug: Omalizumab
Drug: Placebo

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Active, not recruiting
OSA
Drug: Placebo
Drug: AD109

Arm 1 ( Phase 2/3 Run in ):PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary O...

Enrolling
Oral Squamous Cell Carcinoma
Drug: PRV111 (Cisplatin Transmucosal System)
Drug: PRV211 (Intraoperative Cisplatin System)

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Enrolling
Hyposmia
Combination Product: CYR-064

Trial sponsors

I
Otonomy logo
Apnimed logo
P
Sanofi logo
A
AnaptysBio logo
C
E
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems